Navigation Links
Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
Date:5/1/2009

LACHEN, Switzerland, May 1 /PRNewswire/ --

- Company Working With Authorities to Ensure Adequate Supply of Virally Inactivated Plasma Derivatives

The impending influenza pandemic will have implications for global stocks of life-saving blood and blood products, warns Swiss-based global biopharmaceutical company, Octapharma.

But it has reiterated the safety of its plasma derivatives and is working closely with health authorities and plasma suppliers to maintain the safety profile and continuous supply of its lifesaving products.

The threat to blood supplies arises as blood transfusion authorities across the globe remind blood donors to stay away if they have 'flu-like symptoms. In Germany, the Paul Ehrlich Institute, which tests blood products on behalf of the German federal health ministry, has recommended against using blood donated by people who have travelled to countries affected by the swine influenza outbreak or who have been in close contact with people who have 'flu-like symptoms or were in 'flu-affected countries in the previous 14 days.

Octapharma makes plasma derivatives used in a range of medical emergencies. The new swine H1N1 virus, with its epicentre in Mexico, does not endanger the safety of Octapharma's products. Octaplas(R), is a virally inactivated pooled plasma, which can be used in emergency situations whenever plasma transfusion is required.

Currently, Octapharma has sufficient supplies of Octaplas(R) to satisfy usual client demand. Production can be increased by up to 30 percent if demand increases. Octapharma already provides 100 per cent of plasma needs with Octaplas(R) for transfusion in Norway, Finland and Portugal.

During the manufacture of Octaplas(R), the product undergoes a solvent-detergent treatment that destroys the lipid enveloped membrane of a virus, making it inactive and unable to infect.


'/>"/>

SOURCE Octapharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
2. Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
3. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
4. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
5. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
8. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
9. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
10. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
11. Evidence Lacking in Multivitamin Study of Womens Risk of Cancer, Heart Disease or Death, Says Natural Products Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  The Academy of Managed ... Drug Administration,s (FDA,s) draft guidance and proposed rule ... biosimilars, to bear a nonproprietary name with an ... seeking a decision from the FDA on the ... care stakeholders urging the agency to use the ...
(Date:8/27/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... healthcare conferences.  , James E. ... Rodman & Renshaw Investment Conference on Thursday, September 10 ... held at the St. Regis Hotel in ... of the presentation will be available by accessing ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... (FDA) approval of TRELSTAR® 22.5 mg (triptorelin pamoate for ... proven, simple and effective palliative treatment of advanced prostate ... is the first and only six-month intramuscular (IM) GnRH ...
... the bio-pharmaceutical industry, new product commercialization efforts have taken on increased importance. It,s against this backdrop that new product planning ... , ... , ... ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 2Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 3Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 4
(Date:8/31/2015)... ... August 31, 2015 , ... All birth control methods work best ... lowest failure rates among birth control methods. Moreover, no-scalpel vasectomy has many proven advantages ... to have their vasectomy done because they are afraid of complications. , One ...
(Date:8/31/2015)... ... ... GenHart Software, LLC, a rising player in the software game headquartered in Charleston, ... cost effectively as possible, with a belief that the right software can solve any ... and the Charleston business community is taking notice. Just announced, The Harbor Entrepreneur ...
(Date:8/30/2015)... ... August 31, 2015 , ... Avid collector Andrew Hawley from Vintage Rock ... concert posters. This hand colored artwork is one of the most coveted Doors concert ... states, "When the doors played the Shrine, the band was one of the ...
(Date:8/30/2015)... ... August 31, 2015 , ... Intellitec Solutions, ... Convention & Expo October 5th & 6th in San Antonio, TX. Dedicated to ... brings industry professionals from all over the country come to share the latest ...
(Date:8/30/2015)... ... 30, 2015 , ... AvePoint, the established leader ... Silver Sponsor of the Digital Workplace Conference, taking place Sunday, August 30 – ... the event, AvePoint will showcase its file analysis, management, and migration solutions for ...
Breaking Medicine News(10 mins):Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 3Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4
... Baltimore has been chosen by The Gerontological Society of America ... honor, given annually, is a lectureship in geriatrics and is ... - both in research and practice - who is a ... presentation will take place at GSA,s 60th Annual Scientific Meeting, ...
... and ex-husband Kevin Federline continue to duke it out in ... A University of Missouri-Columbia researcher and expert in divorce and ... the damage that can be inflicted on children who are ... almost everything wrong, said Larry Ganong, professor and co-chair of ...
... Novartis Vaccines, in partnership with Public Health, - Seattle & King County and RediClinic, offers ... themselves and the many ... ... the 2006-2007 influenza season peaked in Seattle between mid ...
... for Women,s Health Research Report and Media Briefing ... WASHINGTON, Nov. 13 Women are more,susceptible ... as pregnancy, postpartum and perimenopause, according to a ... a Washington, D.C.-based,advocacy organization, released at a media ...
... enzyme, telomerase, is associated with the uncontrollable proliferation of ... all of human cancers. Since the mid-1990s, when telomerase ... the enzyme as an ideal target for developing broadly ... The Wistar Institute have brought this goal closer by ...
... out of ten people with diabetes are walking around ... problems that could lead to amputation, according to research ... of Clinical Practice. , Published to coincide with ... University of Dundee, has been welcomed by an expert ...
Cached Medicine News:Health News:Britney and K-Fed doing it all wrong, MU family researcher says 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 3Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 4Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 5Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 6Health News:Hormonal Changes and Depression: What is the Connection? 2Health News:Hormonal Changes and Depression: What is the Connection? 3Health News:Hormonal Changes and Depression: What is the Connection? 4Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 2Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 3Health News:63 percent of diabetics risk serious foot problems by wearing the wrong-sized shoes 2
Inquire...
Inquire...
... The compact Allegra X-22 Series is up to ... With a library of 11 rotors, the Allegra X-22 ... Features: Only 18 inches / 46 ... to 22,065 x g 3 different ways to ...
... Fractionation, Proteins and Viruses • ... with fixed-angle rotor • Spin ... 85 mL • Operating temperature ... C • Rotors certified by ...
Medicine Products: